PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
28.86%
G&A growth 50-75% of GNPX's 52.68%. Bruce Berkowitz would examine operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
-40.21%
Other expenses reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine efficiency.
6.04%
Operating expenses growth less than half of GNPX's 17.95%. David Dodd would verify sustainability.
6.04%
Total costs growth less than half of GNPX's 17.95%. David Dodd would verify sustainability.
-100.00%
Interest expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
-40.21%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-66.22%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-6.04%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-333.64%
Other expenses reduction while GNPX shows 46.73% growth. Joel Greenblatt would examine advantage.
-65.74%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
-65.74%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-47.67%
EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
-53.82%
Diluted EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
12.14%
Share count reduction exceeding 1.5x GNPX's 80.76%. David Dodd would verify capital allocation.
7.50%
Diluted share reduction exceeding 1.5x GNPX's 80.76%. David Dodd would verify capital allocation.